MedTrace Logo

Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients

NCT06336213 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-29

No results posted yet for this study

Summary

According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.

Conditions

  • Aortic Aneurysm and Dissection
  • Cardiac Valve Disease
  • Thoracic Aortic Aneurysm
  • Thoracic Aortic Dissection

Interventions

DRUG

Ampicillin-sulbactam

If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.

Sponsors & Collaborators

  • Petrovsky National Research Centre of Surgery

    lead OTHER

Principal Investigators

  • Boris Akselrod, Professor · Petrovsky NRCS

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2026-12-15
Completion
2027-02-15

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06336213 on ClinicalTrials.gov